Prostaglandin E1 Attenuates Pulmonary Artery Remodeling by Activating Phosphorylation of CREB and the PTEN Signaling Pathway

Overview

Journal Sci Rep

Specialty Science

Date 2017 Sep 1

PMID 28855544

Citations 4

Authors

Ying-Ju Lai

Hsao-Hsun Hsu

Gwo-Jyh Chang

Shu-Hui Lin

Wei-Jan Chen

Chung-Chi Huang

Jong-Hwei S Pang

Affiliations

Soon will be listed here.

Abstract

The depletion of cyclic adenosine monophosphate (cAMP) response element binding protein (CREB) and phosphatase and tensin homolog (PTEN) is the critical mediator of pulmonary arterial hypertension (PAH). We hypothesized that the activation of phosphorylated CREB (pCREB) and PTEN could inhibit the AKT signaling pathway to attenuate pulmonary arterial remodeling in rats with monocrotaline-induced PAH. We observed decreased PTEN and pCREB in idiopathic PAH versus control tissue. We reduced PTEN using small interfering RNA in human control pulmonary arterial smooth muscle cells (PASMCs) and observed an increase in pAKT. Consistent with PTEN knockdown in PASMCs, prostaglandin E1 (PGE1) induced pCREB expression to stimulate PTEN protein expression and inhibited pAKT in a time- and dose-dependent manner. The enhanced proliferation and migration of PASMCs following PTEN knockdown were significantly inhibited by PGE1 treatment. The PGE1-induced elevation of PTEN expression in PTEN-depleted PASMCs was decreased by the application of a PKA inhibitor and a CBP-CREB interaction inhibitor. Supplementation with a novel emulsion composition comprising PGE1 in rats with monocrotaline-induced PAH prevented pulmonary arterial remodeling and improved hemodynamics via the induced expression of PTEN. We conclude that PGE1 recruits pCREB/PTEN to decrease the migration and proliferation of PASMCs associated with PAH. This finding elucidates a relevant underlying mechanism of the PGE1/CREB/PTEN signaling pathway to prevent progressive PAH.

Citing Articles

Omega-6 polyunsaturated fatty acids and their metabolites: a potential targeted therapy for pulmonary hypertension.

Wang J, Hu S, Xu Y, Wang T Respir Res. 2025; 26(1):102.

PMID: 40089708 DOI: 10.1186/s12931-025-03172-2.

Fundamental and Targeted Approaches in Pulmonary Arterial Hypertension Treatment.

Park J, Choi Y, Min J, Lee J, Shim G Pharmaceutics. 2025; 17(2).

PMID: 40006591 PMC: 11859843. DOI: 10.3390/pharmaceutics17020224.

RNA m6A methylation and regulatory proteins in pulmonary arterial hypertension.

Wang Z, Zhang Y, Shi J, Yan Y, Zhao L, Kou J Hypertens Res. 2024; 47(5):1273-1287.

PMID: 38438725 DOI: 10.1038/s41440-024-01607-9.

Low-dose vanadium pentoxide perturbed lung metabolism associated with inflammation and fibrosis signaling in male animal and in vitro models.

He X, Jarrell Z, Smith M, Thi Ly V, Hu X, Sueblinvong V Am J Physiol Lung Cell Mol Physiol. 2023; 325(2):L215-L232.

PMID: 37310758 PMC: 10396228. DOI: 10.1152/ajplung.00303.2022.

PTEN: An Emerging Potential Target for Therapeutic Intervention in Respiratory Diseases.

Cai B, Yang L, Do Jung Y, Zhang Y, Liu X, Zhao P Oxid Med Cell Longev. 2022; 2022:4512503.

PMID: 35814272 PMC: 9262564. DOI: 10.1155/2022/4512503.

References

Chen W, Lin K, Lai Y, Yang S, Pang J . Protective effect of propylthiouracil independent of its hypothyroid effect on atherogenesis in cholesterol-fed rabbits: PTEN induction and inhibition of vascular smooth muscle cell proliferation and migration. Circulation. 2004; 110(10):1313-9. DOI: 10.1161/01.CIR.0000140764.15398.F3. View

Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A . 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Rev Esp Cardiol (Engl Ed). 2016; 69(2):177. DOI: 10.1016/j.rec.2016.01.002. View

Chen W, Chen Y, Lin K, Ting C, Yeh Y . Cilostazol promotes vascular smooth muscles cell differentiation through the cAMP response element-binding protein-dependent pathway. Arterioscler Thromb Vasc Biol. 2011; 31(9):2106-13. DOI: 10.1161/ATVBAHA.111.230987. View

Ravi Y, Selvendiran K, Meduru S, Citro L, Naidu S, Khan M . Dysregulation of PTEN in cardiopulmonary vascular remodeling induced by pulmonary hypertension. Cell Biochem Biophys. 2011; 67(2):363-72. PMC: 4596526. DOI: 10.1007/s12013-011-9332-z. View

Harmon E, Porter J, Porter J . Beta-adrenergic receptor activation in immortalized human urothelial cells stimulates inflammatory responses by PKA-independent mechanisms. Cell Commun Signal. 2005; 3:10. PMC: 1198236. DOI: 10.1186/1478-811X-3-10. View

Song M, Salmena L, Pandolfi P . The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012; 13(5):283-96. DOI: 10.1038/nrm3330. View

Kerins D, Murray R, FitzGerald G . Prostacyclin and prostaglandin E1: molecular mechanisms and therapeutic utility. Prog Hemost Thromb. 1991; 10:307-37. View

Horita H, Furgeson S, Ostriker A, Olszewski K, Sullivan T, Villegas L . Selective inactivation of PTEN in smooth muscle cells synergizes with hypoxia to induce severe pulmonary hypertension. J Am Heart Assoc. 2013; 2(3):e000188. PMC: 3698782. DOI: 10.1161/JAHA.113.000188. View

Badesch D, McLaughlin V, Delcroix M, Vizza C, Olschewski H, Sitbon O . Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2004; 43(12 Suppl S):56S-61S. DOI: 10.1016/j.jacc.2004.02.036. View

10.

Gupta V, Ahsan F . Influence of PEI as a core modifying agent on PLGA microspheres of PGE₁, a pulmonary selective vasodilator. Int J Pharm. 2011; 413(1-2):51-62. PMC: 3123904. DOI: 10.1016/j.ijpharm.2011.04.017. View

11.

Alimonti A, Carracedo A, Clohessy J, Trotman L, Nardella C, Egia A . Subtle variations in Pten dose determine cancer susceptibility. Nat Genet. 2010; 42(5):454-8. PMC: 3118559. DOI: 10.1038/ng.556. View

12.

Planchon S, Waite K, Eng C . The nuclear affairs of PTEN. J Cell Sci. 2008; 121(Pt 3):249-53. DOI: 10.1242/jcs.022459. View

13.

Nemenoff R, Simpson P, Furgeson S, Kaplan-Albuquerque N, Crossno J, Garl P . Targeted deletion of PTEN in smooth muscle cells results in vascular remodeling and recruitment of progenitor cells through induction of stromal cell-derived factor-1alpha. Circ Res. 2008; 102(9):1036-45. DOI: 10.1161/CIRCRESAHA.107.169896. View

14.

Parker D, Ferreri K, Nakajima T, LaMorte V, Evans R, Koerber S . Phosphorylation of CREB at Ser-133 induces complex formation with CREB-binding protein via a direct mechanism. Mol Cell Biol. 1996; 16(2):694-703. PMC: 231049. DOI: 10.1128/MCB.16.2.694. View

15.

Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin L . Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002; 347(5):322-9. DOI: 10.1056/NEJMoa020204. View

16.

Li X, Zhang X, Leathers R, Makino A, Huang C, Parsa P . Notch3 signaling promotes the development of pulmonary arterial hypertension. Nat Med. 2009; 15(11):1289-97. PMC: 2780347. DOI: 10.1038/nm.2021. View

17.

Kasper L, Lerach S, Wang J, Wu S, Jeevan T, Brindle P . CBP/p300 double null cells reveal effect of coactivator level and diversity on CREB transactivation. EMBO J. 2010; 29(21):3660-72. PMC: 2982758. DOI: 10.1038/emboj.2010.235. View

18.

Schermuly R, Ghofrani H, Wilkins M, Grimminger F . Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol. 2011; 8(8):443-55. PMC: 7097518. DOI: 10.1038/nrcardio.2011.87. View

19.

Gu T, Zhang Z, Wang J, Guo J, Shen W, Yin Y . CREB is a novel nuclear target of PTEN phosphatase. Cancer Res. 2011; 71(8):2821-5. PMC: 3105967. DOI: 10.1158/0008-5472.CAN-10-3399. View

20.

Nisbet R, Bland J, Kleinhenz D, Mitchell P, Walp E, Sutliff R . Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model. Am J Respir Cell Mol Biol. 2009; 42(4):482-90. PMC: 2848739. DOI: 10.1165/rcmb.2008-0132OC. View